Beijing, September 02, 2024 – R&D-based Pharmaceutical Association Committee (RDPAC) has announced following the voting among its 2024-2025 Executive Committee members, Sean Shan, Senior Vice President of Takeda Pharmaceutical Company Ltd., President of Takeda China, has been appointed as Vice Chair of the RDPAC Executive Committee for 2024-2025 effective as of September 02, 2024.
Sean Shan
Vice Chair of the RDPAC Executive Committee for 2024-2025
Senior Vice President of Takeda Pharmaceutical Company Ltd., President of Takeda China
Sean expressed his gratitude: “I am honored to take on the role of Vice Chair at RDPAC and continue contributing to the Executive Committee. In today’s rapidly evolving pharmaceutical landscape in China, especially under the guidance of an innovation-driven strategy, RDPAC plays a pivotal role as a platform uniting global pharmaceutical innovation. It bears the responsibility of advancing industry progress and enhancing public health. I look forward to working closely with my colleagues on the Executive Committee to deepen collaboration across the healthcare sector, accelerate new drug development and accessibility, and contribute to the ‘Healthy China’ Initiative.”
The 2024-2025 RDPAC Executive Committee updates are now complete. The updated list of the RDPAC 2024-2025 Executive Committee is as follows:
Note: Members are listed in alphabetical order based on the English name of the represented member company.
Jean-Christophe Pointeau, Chairman of the RDPAC Executive Committee, Global Senior Vice President of Pfizer, President of Pfizer China, extended sincere congratulations to the new members on behalf of the entire Executive Committee. He stated: “We are pleased to welcome Mr. Sean Shan to the RDPAC Executive Committee leadership team. We look forward to the fresh vision and energy that Sean will bring to the Executive Committee. As an industry organization, RDPAC will continue to collaborate with key stakeholders, serving as a bridge between government and industry. We remain committed to supporting the development of a scientific, efficient regulatory system, fostering an innovation-friendly healthcare system, strengthening legal protections for pharmaceutical innovation, and building a vibrant ecosystem for pharmaceutical innovation to achieve high-quality development of China’s pharmaceutical industry and support the achievement of the ‘Healthy China’ goals.”
